Progress of hematological malignant tumors
10.3760/cma.j.issn.1009-9921.2018.01.001
- VernacularTitle:血液系统恶性肿瘤研究进展
- Author:
Zhijian CAO
1
;
Jun MA
Author Information
1. 150010,哈尔滨血液病肿瘤研究所
- Keywords:
Hematologic diseases;
Therapeutic advance;
Lymphoma;
Leukemia
- From:
Journal of Leukemia & Lymphoma
2018;27(1):1-3
- CountryChina
- Language:Chinese
-
Abstract:
The 59th American Society of Hematology (ASH) Annual Meeting is known as the most powerful hematological meeting around the world. The outcomes in the meeting showed the progress of current hematological diseases from the fundamental research to the clinical practice, from the diagnosis to the treatment. The 59th ASH Annual Meeting covered the contents from the improvement of the formal treatment of acute myelogenous leukemia to the strategies of the aggressive B-cell lymphoma, from the prospect on myelodysplastic syndromes to the influence of biological features on the treatment strategies of indolent lymphoma, from the individualized treatment of chronic lymphocytic leukemia to the study on acquired or hereditary bone marrow failure. The inspiring outcomes from the scholars in China have gained good reputations from the international.
